IP Library Granted Patent US 9,849,170
Granted Patent B2
US 9,849,170 · App. 14/766,922 · Granted Dec 26, 2017

Microneedle coating composition and microneedle device

Inventors: Kazuya Machida (Tsukuba, JP); Seiji Tokumoto (Tsukuba, JP); Kazuyoshi Kaminaka (Kikuchi, JP); Yuji Ishikawa (Kumamoto, JP)
Assignees: HISAMITSU PHARMACEUTICAL CO., INC.; THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
A61K39/12A61K9/0021A61K47/12A61K47/183C12N7/00A61K2039/54C12N2770/24134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,849,170
App. No.
14/766,922
Granted
Dec 26, 2017
Kind
B2
Abstract

Disclosed is a microneedle coating composition comprising a Japanese encephalitis vaccine antigen, a basic amino acid, and an acid, wherein the mole number of the acid for one mole of the basic amino acid is larger than 1/(N+1) and less than 2, where N represents the valence of the acid.

Claims (20)

1. A microneedle coating composition comprising:

a Japanese encephalitis vaccine antigen;

a basic amino acid in a concentration of 20% w/w or more based on the total mass of the microneedle coating composition; and

an acid in a concentration of 5% to 50% w/w based on the total mass of the microneedle coating composition, wherein the acid is at least one acid selected from the group consisting of phosphoric acid, lactic acid, benzoic acid, maleic acid, citric acid, tartaric acid, succinic acid, ascorbic acid and aspartic acid, wherein

a mole number of the acid for one mole of the basic amino acid is larger than 1/(N+1) and less than 2, where N represents a valence of the acid.

2. The microneedle coating composition according to claim 1 , wherein the acid has a melting point of 40° C. or more.

3. The microneedle coating composition according to claim 1 , wherein the basic amino acid is arginine.

4. The microneedle coating composition according to claim 3 , comprising lysine or lysine hydrochloride.

5. The microneedle coating composition according to claim 1 , comprising lysine or lysine hydrochloride.

6. The microneedle coating composition according to claim 1 , wherein a concentration of the basic amino acid is 30% w/w or more based on the total mass of the microneedle coating composition.

7. A microneedle device comprising:

a microneedle; and

a coating layer formed from the microneedle coating composition according to claim 1 on the microneedle.

8. The microneedle device according to claim 7 , wherein the coating layer is formed on a tip portion of the microneedle.

9. A microneedle device comprising:

a microneedle; and

a coating layer formed from the microneedle coating composition according to claim 3 on the microneedle.

10. A microneedle device comprising:

a microneedle; and

a coating layer formed from the microneedle coating composition according to claim 4 on the microneedle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2016
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE; HISAMITSU PHARMACEUTICAL CO., INC.
To: HISAMITSU PHARMACEUTICAL CO., INC.
Reel/Frame 037886/0989 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2015
From: MACHIDA, KAZUYA; TOKUMOTO, SEIJI; KAMINAKA, KAZUYOSHI; ISHIKAWA, YUJI
To: HISAMITSU PHARMACEUTICAL CO., INC.; THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 036645/0388 →
Priority Claims (1)
JP 2013-025955 · Feb 13, 2013 · national
Continuity (1)
Related Publication 20160000898A1 · Jan 7, 2016